Kenneth G Saag MD

Rheumatology•Birmingham, AL

Rheumatoid Arthritis & Related, Spondyloarthropathy

Professor, Medicine, University of Alabama School of Medicine

Join to View Full Profile

1717 6th Ave SBirmingham, AL 35233
Phone+1 800-822-8816
Fax+1 205-583-8060

Education & Training

University of Iowa Hospitals and ClinicsFellowship, Rheumatology, 1990 - 1993
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1987 - 1989
McGaw Medical Center of Northwestern UniversityInternship, Internal Medicine, 1986 - 1987
Northwestern University The Feinberg School of MedicineClass of 1986

Certifications & Licensure

AL State Medical License 1998 - 2025
IA State Medical License 1990 - 2000
IL State Medical License 1986 - 1993
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

Member Association of American Physicians, 2015
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Fellow (FACP) American College of Physicians, 1995
Fellow (FACR) American College of Rheumatology
Join now to see all

Clinical Trials

Improving Care of Osteoporosis: Multi-Modal Intervention to Increase Testing and Treatment (ICOMMIITT) Start of enrollment: 2010 May 01
Completed
Not Applicable
Improving Bone Health Among Rheumatoid Arthritis (RA) Patients on Chronic Glucocorticoids Start of enrollment: 2010 Sep 01
Completed
Phase 4
Patient Activation After DXA Result Notification Start of enrollment: 2012 Feb 01
Completed
Not Applicable
A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care Start of enrollment: 2013 Aug 01
Completed
Not Applicable
Center of Research Translation (CORT) Project 2 Start of enrollment: 2014 Jul 01
Completed
Phase 2, Phase 3
Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study Start of enrollment: 2014 Jun 01
Completed
Phase 4
REduCing Immunogenicity to PegloticasE (RECIPE) Study Start of enrollment: 2018 Jun 14
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 s...
Kenneth G Saag, Nicola Dalbeth, Chi-Yuan Hsu, Chang-Fu Kuo, George Nuki
Contemporary Clinical Trials. 2025-04-01
Outpatient Gout Follow-up After an Emergency Department Visit for Gout Flares.
Lesley E Jackson, Elizabeth Lopez, Kenneth G Saag, Rahima Begum, Gary Cutter
Journal of Clinical Rheumatology. 2025-03-19
The Design of a Randomized Controlled Active Comparator Strategy Trial for Gout: Treat to Target Serum Urate Versus Treat to Avoid Symptoms.
Daniel H Solomon, Misti Paudel, Shravani Chitineni, Ana Fernandes, Tammy Pham
ACR Open Rheumatology. 2025-03-01

Journal Articles

Recommendations Regarding the Reporting of Economic Evaluations in Osteoporosis
S Silverman, K G Saag, S V Bukata, D T Gold, Osteoporosis international
Long‐Term Safety of Rituximab in Rheumatoid Arthritis: Analysis from the SUNSTONE Registry
Kenneth Saag, Daniel E Furst, Kevin L Winthrop, Arthritis Care & Research
Correction to: Hip Fracture Trends in the United States, 2002 to 2015
R F Gagel, E Siris, K G Saag, J R Curtis, Osteoporosis international
Opioids vs Nonopioids for Chronic Back, Hip, or Knee Pain
Jasvinder A Singh, Kenneth G Saag, Jeffrey R Curtis, JAMA
Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients with Selected Conditions*
K Saag, J R Curtis, Journal of Bone and Mineral Research
Join now to see all

Lectures

Osteoporosis and Vitamin D
ENDO 2019 - New Orleans, LA - 3/23/2019

Other

Efficacy and Safety of Febuxostat Extended Release and Immediate Release in Patients with Gout and Moderate Renal Impairment: Phase II Placebo-Controlled Study
Kenneth Saag, MD, BioMed Central
https://www.doximity.com/articles/47eb89b0-8f9e-4db6-add1-f5a2e4ce0763
UpToDate, Wolters Kluwer Health - 2013-03-06
Efficacy and Safety of Febuxostat Extended Release and Immediate Release in Patients with Gout and Moderate Renal Impairment: Phase II Placebo-Controlled Study
Kenneth Saag, MD, BioMed Central
https://www.doximity.com/articles/47eb89b0-8f9e-4db6-add1-f5a2e4ce0763
UpToDate, Wolters Kluwer Health - 2012-04-18
Efficacy and Safety of Febuxostat Extended Release and Immediate Release in Patients with Gout and Moderate Renal Impairment: Phase II Placebo-Controlled Study
Kenneth Saag, MD, BioMed Central
https://www.doximity.com/articles/47eb89b0-8f9e-4db6-add1-f5a2e4ce0763
UpToDate, Wolters Kluwer Health - 2012-04-18
Efficacy and Safety of Febuxostat Extended Release and Immediate Release in Patients with Gout and Moderate Renal Impairment: Phase II Placebo-Controlled Study
Kenneth Saag, MD, BioMed Central
https://www.doximity.com/articles/47eb89b0-8f9e-4db6-add1-f5a2e4ce0763
UpToDate, Wolters Kluwer Health - 2013-04-08
Efficacy and Safety of Febuxostat Extended Release and Immediate Release in Patients with Gout and Moderate Renal Impairment: Phase II Placebo-Controlled Study
Kenneth Saag, MD, BioMed Central
https://www.doximity.com/articles/47eb89b0-8f9e-4db6-add1-f5a2e4ce0763
UpToDate, Wolters Kluwer Health - 2012-12-04
Join now to see all

Press Mentions

Fracture & an Aging WorldSeptember 24th, 2024
Novel Gout Drug Passes Mid-Stage TestJanuary 20th, 2023
Themes of Drama, Heroism & New Challenges Threaded President’s & Keynote Addresses at ACR Convergence 2022November 18th, 2022
Join now to see all

Grant Support

CTSA K12 Program at the University of Alabama at BirminghamUNIVERSITY OF ALABAMA AT BIRMINGHAM2024–2029
INvestigations In Gout, Hyperuricemia, and comorbidiTies (INSIGHT) Center of Research Translation (CORT)UNIVERSITY OF ALABAMA AT BIRMINGHAM2012–2025
Activating Patients To Reduce Osteoporosis (APROPOS)National Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
UAB Deep South Arthritis And Musculoskeletal CertsAgency For Healthcare Research And Quality2011
Mid-Career Investigator Award (For Kenneth G. Saag, MD, Msc)National Institute Of Arthritis And Musculoskeletal And Skin Diseases2010–2011
UAB Health Services &Outcomes Research Training ProgramAgency For Healthcare Research And Quality2009–2011
Improving Care Of Osteoporosis: Multi-Modal Interventions To Increase TestingNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2008–2011
Comprehensive Minority And Health Disparities Research CenterNational Center On Minority Health And Health Disparities2010
UAB T32 In Comparative Effectiveness ResearchAgency For Healthcare Research And Quality2010
UAB K 12 In Comparative Effectiveness ResearchAgency For Healthcare Research And Quality2010
Deep South Musculoskeletal (DSM) CertsAgency For Healthcare Research And Quality2007–2010
Mid-Career Investigator Award For Kenneth G. SaagNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2005–2009
Safety Assessment Of Anti-Tnf Agents Used In Autoimmune DiseaseAgency For Healthcare Research And Quality2008
Androgen-Deprivation Therapy For Prostate Cancer And Bone HealthNational Center For Research Resources2006–2007
UAB CERT Of Musculoskeletal DisordersAgency For Healthcare Research And Quality2000–2006
UAB Certs Of Musculoskeletal DisordersAgency For Healthcare Research And Quality2005
Improving Quality Of Care In Steroid Induced OsteoporosisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2002
Long Term Safety And Toxicity Monitoring For NsaidsNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2000–2001
Osteonecrosis Among Renal Transplant RecipientsNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1999–2001
Osteonecrosis Among Renal Transplant PatientsNational Center For Research Resources2000